SkinBioTherapeutics (LON:SBTX) Stock Price Down 3.5% – Here’s What Happened

SkinBioTherapeutics plc (LON:SBTX)’s stock price dropped 3.5% during mid-day trading on Tuesday . The stock traded as low as GBX 19.50 and last traded at GBX 19.78. Approximately 253,497 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 1,600,479 shares. The stock had previously closed at GBX 20.50.

SkinBioTherapeutics Trading Down 3.5%

The firm has a market capitalization of £51.18 million, a price-to-earnings ratio of -63.80 and a beta of 2.01. The business’s 50-day moving average price is GBX 16.75 and its 200 day moving average price is GBX 15.99. The company has a debt-to-equity ratio of 27.57, a current ratio of 0.93 and a quick ratio of 10.01.

SkinBioTherapeutics (LON:SBTX) last released its quarterly earnings results on Monday, December 8th. The company reported GBX (0.31) earnings per share for the quarter. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis. The company has an agreement with Croda Plc; and operates two research programmes with the University of Manchester, an oral programme and an inflammation study.